Skip Navigation

Annals of Oncology 2009 20(Supplement 4):iv71-iv72; doi:10.1093/annonc/mdp133
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sørensen, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sørensen, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

ESMO clinical recommendations

Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

M. Sørensen1, E. Felip2 and On behalf of the ESMO Guidelines Working Group*

1 Department of Oncology, Unit for Experimental Cancer Treatment, Rigshospitalet, Copenhagen, Denmark
2 Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain

* Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland; E-mail: clinicalrecommendations@esmo.org

The first 10% of the full text of this article appears below.


   incidence
 
The crude incidence of lung cancer in the European Union in 2002 was 55.5/100 000/year, mortality rate being 50.6/100 000/year. Rates among men were 87.7 and 80.1/100 000/year, and among women 24.8 and 22.4/100 000/year, respectively (GLOBOCAN 2002, http://www-dep.iarc.fr). Small-cell lung cancer (SCLC) accounts for 15–18% of all . . . [Full Text of this Article]


   diagnosis
 

   staging and risk assessment
 
limited disease
extensive disease

   treatment of limited disease
 

   treatment of extensive disease
 

   second-line chemotherapy
 

   response evaluation
 

   follow-up
 

   note
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?